<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38451">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847222</url>
  </required_header>
  <id_info>
    <org_study_id>SGHV-005</org_study_id>
    <nct_id>NCT01847222</nct_id>
  </id_info>
  <brief_title>An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.</brief_title>
  <official_title>An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolong Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolong Pharmaceuticals</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety assessment of SANGUINATE™ in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE™ in Healthy
      Volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events of SANGUINATE™</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-bHb-CO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SANGUINATE™</intervention_name>
    <description>PEG-bHb-CO</description>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <other_name>PEG-bHb-CO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Volunteers;

          -  Age ≥18 years and ≤45 years;

          -  BMI ≥20- ≤30 kg/m²

          -  No clinically significant screening observations

        Exclusion Criteria:

          -  Female volunteers;

          -  Any history of significant cardiac, renal, neurologic, metabolic, pulmonary,
             gastrointestinal, chronic hepatic disease or any other disease which in the judgment
             of the Investigator would interfere with the study or confound the results;

          -  History of allergy or major allergic reactions considered to be clinically
             significant by the Investigator;

          -  Any screening assessment determined to be clinically significant by the Investigator;

          -  Donate blood within 60 days of screening or otherwise experienced blood loss &gt;250 mL
             within the same period;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Facility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Facility</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Brenner, MD</last_name>
      <phone>972 4 8543520</phone>
      <email>b_brenner@rambam.health.gov</email>
    </contact>
    <investigator>
      <last_name>Benjamin Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 3, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
